Literature DB >> 991935

The distribution and metabolism of chlorpromazine in rats and the relationship to effects on cerebral monoamine metabolism.

F A Wiesel, G Alfredsson.   

Abstract

Rats were injected with chlorpromazine (CPZ), 21 mumoles/kg (7.5 mg/kg) i.p., and killed after different time intervals up to 24 h. Mass fragmentographic methods were used to determine the levels of CPZ, monodemethyl-chlorpromazine (nor1-CPZ) and 7-hydroxy-chlorpromazine (7-OH-CPZ) in brain and blood and dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA) and 5-hydroxy-3-indoleacetic acid (5-HIAA) in the striatum. Significant correlations between the brain and blood concentrations of CPZ as well as its active metabolites and the levels of DOPAC and HVA were obtained at several time points. The similarity between the time curves for CPZ dominantly the unchanged drug in the brain which determines the acceleration of DA metabolism.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 991935     DOI: 10.1016/0014-2999(76)90061-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  Neurochemistry of withdrawal emergent symptoms in children.

Authors:  B G Winsberg; M J Hurwic; J Sverd; A Klutch
Journal:  Psychopharmacology (Berl)       Date:  1978-03-01       Impact factor: 4.530

2.  Levels of chlorpromazine and its active metabolites in rat brain and the relationship to central monoamine metabolism and prolactin secretion.

Authors:  G Alfredsson; F A Wiesel; P Skett
Journal:  Psychopharmacology (Berl)       Date:  1977-06-06       Impact factor: 4.530

3.  The in vivo distribution of an antidepressant drug (DMI) in male and female rats.

Authors:  A Biegon; D Samuel
Journal:  Psychopharmacology (Berl)       Date:  1979-11       Impact factor: 4.530

4.  Repurposing chlorpromazine to treat COVID-19: The reCoVery study.

Authors:  M Plaze; D Attali; A-C Petit; M Blatzer; E Simon-Loriere; F Vinckier; A Cachia; F Chrétien; R Gaillard
Journal:  Encephale       Date:  2020-05-16       Impact factor: 1.291

5.  [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study].

Authors:  M Plaze; D Attali; A-C Petit; M Blatzer; E Simon-Loriere; F Vinckier; A Cachia; F Chrétien; R Gaillard
Journal:  Encephale       Date:  2020-04-29       Impact factor: 1.291

6.  Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine.

Authors:  Marion Plaze; David Attali; Matthieu Prot; Anne-Cécile Petit; Michael Blatzer; Fabien Vinckier; Laurine Levillayer; Jeanne Chiaravalli; Florent Perin-Dureau; Arnaud Cachia; Gérard Friedlander; Fabrice Chrétien; Etienne Simon-Loriere; Raphaël Gaillard
Journal:  Int J Antimicrob Agents       Date:  2020-12-30       Impact factor: 5.283

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.